NasdaqGS:CYTKBiotechs
Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns
Cytokinetics (CYTK) has capped FY 2025 with Q4 revenue of US$17.8 million and a basic EPS loss of US$1.52, anchored by a net loss of US$183.0 million. This sets the tone for how investors are reading the latest update against a year of heavy spending. Over recent periods, the company has seen quarterly revenue range from US$1.6 million to US$66.8 million in FY 2025, while basic EPS losses have moved between US$1.12 and US$2.55. This gives a clear picture of a business that is still investing...